19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis

2023

Girard N, Leighl N, Ohe Y, Kim TM, Demirdjian L, Bourla AB, Sultan AA, Mahadevia P, Bauml JM, Sabari J